Structure Therapeutics’ Post

Check out the fantastic news from our portfolio company Structure Therapeutics (NASDAQ: GPCR)! The company announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, along with positive topline results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives. Topline results include that in the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2%1 (p<0.0001) at 12 weeks; A capsule to tablet PK study designed to explore a new tablet formulation of GSBR-1290 demonstrated a placebo-adjusted mean weight loss of up to 6.9% (p<0.0001) with the tablet formulation at 12 weeks; GSBR-1290 demonstrated generally favorable safety and tolerability results following repeated, daily dosing up to 120mg. #MedicalInnovation #ObesityResearch #ClinicalTrials #QimingPortfolio #QimingHealthcare

The sad reality of using pills and procedures over lifestyle change is that those on GLP-1RAs aren't eating any healthier. 95% of serotonin is produced in the gut, and GLP-1 drugs don't lend to eating more fiber which is necessary to fuel the gut flora responsible for serotonin production. Perhaps the limited fiber that was being consumed before taking the drug was further reduced, and thus the correlation between GLP-1RAs and increased use of antidepressants. https://lnkd.in/g6Y535CD

Tirzepatide 25mg It is a dual glucose-dependent insulinotropic polypeptide (GLP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. https://lnkd.in/gYKTewa6

Have you been hearing about Ozempic in the news and wanting to learn more? Check out Brianna Evans’ article “Glucagon-like Peptide-1 Receptor Agonists: Possible Panacea?” 🔗 https://lnkd.in/gze9TaNr TL;DR -Ozempic® is a GLP-1RA, a class of drug which can have many clinical uses -GLP-1RAs stimulate insulin release and lower blood glucose levels -More work is needed to fully understand the mechanism of GLP-1RAs

What is the optimal strategy for unresectable stage III #nsclc after chemoradiation in #EGFR mutant NSCLC? Retrospective look (n=136) shows 2y rwPFS rate 86% with osimertinib, 30% w/ durvalumab, 27% w/ observation. Await prospective data from the phase III LAURA trial.

Tirzepatide, also known as LY3298176, is a novel insulin-glucagon-like peptide-1 receptor (GLP-1 receptor) agonist. https://lnkd.in/gPdrsxJs

Pharmacological properties of cardiovascular histamine H1 receptor binding sites: characterisation with 2-phenylhistamines https://t.co/tXVPSbK9YS #EurekaMag

Binding sites and design strategies for small molecule GLP-1R Agonists A review illustrating the structures of the GLP-1R and the diversity of receptor ligand interactions that may inspire future studies of small molecule ligands targeting GLP-1R. https://lnkd.in/gKKdh9BU

Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment #MAFLD  👉https://lnkd.in/d4NkHdrR

Ligand efficacy modulates conformational dynamics of the µ-opioid receptor [ Molecule ]